Researchers compare long-acting and intermediate insulin

Long-acting insulin is slightly safer and more effective than intermediate-acting insulin for patients with Type 1 diabetes, according to a review more than 30 studies published in the BMJ.

Scientists looked at once-daily and twice-daily doses of both long- and intermediate-acting insulin, ranking their efficacy safety and cost-effectiveness.  

“In patients with type 1 diabetes, we found that long-acting insulin is superior to intermediate-acting insulin when it came to controlling blood sugar, preventing weight gain and treating severe hypoglycaemia,&rdquo